Your browser doesn't support javascript.
loading
The use of combination therapy for the improvement of colistin activity against bacterial biofilm.
Jalil, Abduladheem Turki; Alrawe, Rawaa Turki Abdulghafoor; Al-Saffar, Montaha A; Shaghnab, Murtadha Lafta; Merza, Muna S; Abosaooda, Munther; Latef, Rahim.
Afiliação
  • Jalil AT; College of Medicine, University of Thi-Qar, Al-Nasiriya, Iraq. abedalazeem799@gmail.com.
  • Alrawe RTA; Education College for Women, Department of Biology, University of Anbar, Anbar, Iraq.
  • Al-Saffar MA; Community Health Department, Institute of Medical Technology/Baghdad, Middle Technical University, Baghdad, Iraq.
  • Shaghnab ML; National University of Science and Technology, Nasiriyah, Dhi Qar, Iraq.
  • Merza MS; Prosthetic Dental Techniques Department, Al-Mustaqbal University College, Babylon, 51001, Iraq.
  • Abosaooda M; Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq.
  • Latef R; Medical Technical College, Al-Farahidi University, Baghdad, Iraq.
Braz J Microbiol ; 55(1): 411-427, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38030866
Colistin is used as a last resort for the management of infections caused by multi-drug resistant (MDR) bacteria. However, the use of this antibiotic could lead to different side effects, such as nephrotoxicity, in most patients, and the high prevalence of colistin-resistant strains restricts the use of colistin in the clinical setting. Additionally, colistin could induce resistance through the increased formation of biofilm; biofilm-embedded cells are highly resistant to antibiotics, and as with other antibiotics, colistin is impaired by bacteria in the biofilm community. In this regard, the researchers used combination therapy for the enhancement of colistin activity against bacterial biofilm, especially MDR bacteria. Different antibacterial agents, such as antimicrobial peptides, bacteriophages, natural compounds, antibiotics from different families, N-acetylcysteine, and quorum-sensing inhibitors, showed promising results when combined with colistin. Additionally, the use of different drug platforms could also boost the efficacy of this antibiotic against biofilm. The mentioned colistin-based combination therapy not only could suppress the formation of biofilm but also could destroy the established biofilm. These kinds of treatments also avoided the emergence of colistin-resistant subpopulations, reduced the required dosage of colistin for inhibition of biofilm, and finally enhanced the dosage of this antibiotic at the site of infection. However, the exact interaction of colistin with other antibacterial agents has not been elucidated yet; therefore, further studies are required to identify the precise mechanism underlying the efficient removal of biofilms by colistin-based combination therapy.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colistina / Antibacterianos Limite: Humans Idioma: En Revista: Braz J Microbiol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Iraque País de publicação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colistina / Antibacterianos Limite: Humans Idioma: En Revista: Braz J Microbiol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Iraque País de publicação: Brasil